Revance Therapeutics, Inc. (NASDAQ:RVNC) CEO Sells $655,398.26 in Stock

Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) CEO Mark J. Foley sold 26,279 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $24.94, for a total transaction of $655,398.26. Following the completion of the transaction, the chief executive officer now owns 866,654 shares […]

Related Keywords

United States ,Markj Foley ,Piper Sandler ,Thrivent Financial For Lutherans ,Nasdaq ,Wells Fargo Company ,Securities Exchange Commission ,Centaurus Financial Inc ,England Research Management Inc ,International Biotechnology Trust ,Needham Company ,Revance Therapeutics Inc ,Revance Therapeutics Company Profile ,Ameriprise Financial Inc ,Revance Therapeutics ,Free Report ,Exchange Commission ,England Research ,Biotechnology Trust ,Thrivent Financial ,Revance Therapeutics Daily ,